Sanofi India Limited has initiated a postal ballot process to seek shareholder approval for the appointment of Deepak Arora as Director and Managing Director of the company. The proposed appointment, if approved, will be for a three-year term from October 27, 2025, to October 26, 2028.

Key Details of the Appointment

• Position: Director and Managing Director
• Candidate: Mr. Deepak Arora (DIN: 07495638)
• Term: 3 years (October 27, 2025 - October 26, 2028)
• Age: 52 years
• Educational Background: Bachelor's degree in Botany & Zoology from the University of Lucknow and MBA from Indira Gandhi National Open University

Voting Process

Sanofi India has opted for an e-voting process for this postal ballot:

• E-voting Period: November 18, 2025 (9:00 a.m. IST) to December 17, 2025 (5:00 p.m. IST)
• Result Declaration: On or before December 19, 2025

Proposed Remuneration

The company has outlined the following remuneration structure for Mr. Arora:

Additional benefits include provident fund, gratuity, increments, relocation support, leave travel allowance, insurance coverage, and other perquisites as per company policy.

Professional Background

Mr. Arora brings over 30 years of experience in the pharmaceutical and healthcare sectors. His expertise spans sales and marketing leadership, brand development, product management, and business acquisition. He has worked in both local and global matrix environments, with exposure to international markets including the US, Europe, Japan, Africa, and the Middle East.

Central Government Approval

It's important to note that Mr. Arora's appointment requires Central Government approval as he has not been residing in India for the required 12 months prior to the proposed appointment date. This is in line with the provisions of Schedule V of the Companies Act, 2013.

Board's Recommendation

The Board of Directors of Sanofi India has expressed confidence in Mr. Arora's capabilities, stating that his knowledge and experience will be of immense value to the company. They have recommended the approval of the ordinary resolutions for his appointment.

Shareholders of Sanofi India Limited are encouraged to participate in the e-voting process to cast their votes on this significant corporate action. The outcome of this postal ballot will shape the leadership of the company for the next three years, potentially influencing its strategic direction and performance in the Indian pharmaceutical market.

Sanofi India Limited , a prominent player in the pharmaceutical sector, has released its financial results for the third quarter ended September 30. The company demonstrated mixed performance, with improved profitability margins despite a decline in revenue and net profit.

Financial Highlights

Key Takeaways

1. Revenue Decline: Sanofi India experienced a year-over-year decrease in revenue from ₹524.00 crore to ₹475.40 crore, representing a decline of 9.30%.

2. Improved EBITDA: Despite the revenue drop, the company's EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased from ₹120.00 crore to ₹134.00 crore, showing a growth of 11.67%.

3. EBITDA Margin Expansion: The EBITDA margin saw a significant improvement, rising from 23.00% to 28.00%, indicating enhanced operational efficiency.

4. Net Profit Decrease: The company's net profit declined from ₹82.00 crore to ₹76.00 crore, a decrease of 7.32% compared to the same quarter last year.

Corporate Actions and Strategy

1. Interim Dividend: The Board declared an interim dividend of ₹75 per equity share. The record date for this dividend is set for November 7.

2. Portfolio Streamlining: Sanofi India is focusing on streamlining its portfolio to concentrate on core therapeutic areas, including diabetes and cardiovascular treatments.

3. Cost Efficiency: The company's improved EBITDA and operating margin are attributed to cost efficiency measures and a favorable product mix.

Market Performance

Following the results announcement, Sanofi India's shares remained largely unchanged at ₹4,747.00. The stock has gained 22% year-to-date, indicating overall positive investor sentiment despite the mixed quarterly results.

The mixed results reflect the challenging environment in which Sanofi India operates. While the company has managed to improve its operational efficiency, as evidenced by the higher EBITDA and margin, the decline in revenue and net profit indicates ongoing market pressures.

Investors and stakeholders will likely be watching closely to see how Sanofi India's strategic moves, such as portfolio streamlining and cost efficiency measures, will impact its performance in the coming quarters. The company's ability to maintain its improved margins while addressing the revenue decline will be crucial for its future financial health.